S
12.05
0.40 (3.43%)
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Bullish | Bullish |
Biotechnology (Global) | Bullish | Bullish | |
Stock | Stoke Therapeutics, Inc. | Bullish | - |
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Value |
Ownership
Name | Date | Shares Held |
---|---|---|
Skorpios Trust | 31 Dec 2023 | 14,443,681 |
52 Weeks Range |
3.35 - 16.40
|
|
Price Target Range | ||
High | 35.00 (HC Wainwright & Co., 190.46%) | Buy |
Median | 21.00 (74.27%) | |
Low | 13.00 (JP Morgan, 7.88%) | Neutral |
Average | 21.60 (79.25%) | |
Total | 1 Neutral, 1 Outperform, 3 Buy |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Needham | 11 Apr 2024 | 22.00 (82.57%) | Buy | 13.50 |
26 Mar 2024 | 22.00 (82.57%) | Buy | 10.29 | |
Canaccord Genuity | 26 Mar 2024 | 21.00 (74.27%) | Buy | 10.29 |
HC Wainwright & Co. | 26 Mar 2024 | 35.00 (190.46%) | Buy | 10.29 |
JP Morgan | 26 Mar 2024 | 13.00 (7.88%) | Neutral | 10.29 |
Wedbush | 26 Mar 2024 | 17.00 (41.08%) | Outperform | 10.29 |
No data within this time range.
Date | Type | Details |
---|---|---|
29 Apr 2024 | Announcement | Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer |
17 Apr 2024 | Announcement | Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer |
04 Apr 2024 | Announcement | Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference |
27 Mar 2024 | Announcement | Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering |
26 Mar 2024 | Announcement | Stoke Therapeutics Announces Proposed Public Offering |
25 Mar 2024 | Announcement | Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results |
25 Mar 2024 | Announcement | Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome |
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |